<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02978508</url>
  </required_header>
  <id_info>
    <org_study_id>MAP-8184</org_study_id>
    <nct_id>NCT02978508</nct_id>
  </id_info>
  <brief_title>Bio-equivalence Study Comparing Permethrin Cream, 5% With Elimite in Patients With Active Scabies.</brief_title>
  <official_title>A Multi-center, Double-blind, Randomized, Parallel-group Study Comparing Permethrin Cream, 5% With Elimite™ in Patients With Active Scabies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayne Pharma International Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>bioRASI, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayne Pharma International Pty Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, double-blind, randomized, two arm parallel design study. This study&#xD;
      is comprised of two phases: screening and treatment. The screening period will be up to 5&#xD;
      days, followed by the treatment phase of 28±4 days. During the treatment phase subjects will&#xD;
      be randomized to receive either test or reference treatments in a double-blind manner in an&#xD;
      outpatient setting. Randomization of subjects will be in a 1:1 ratio for the test and&#xD;
      reference drug arms and will be stratified by site.&#xD;
&#xD;
      Screening will begin at visit 1, during which eligibility will be determined and prohibited&#xD;
      treatments will be discontinued. Randomization will occur following the confirmation of the&#xD;
      eligibility criteria at visit 2 (baseline, Day 1) i.e. initiation of treatment phase. The&#xD;
      treatment phase will be 28±4 days in duration wherein subject will receive treatment with&#xD;
      investigational product (either test or reference) on Day 1 or Baseline (visit 2). Safety and&#xD;
      tolerability assessments will be performed on Day 7 (visit 3). Efficacy, safety and&#xD;
      tolerability will be assessed on Day 14 (visit 4) followed by the End of study visit on Day&#xD;
      28 (visit 5). If positive identification of scabies is confirmed at Day 14 (visit 4), the&#xD;
      subject will be retreated with the second application of the investigational product.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic absorption of permethrin cream is limited to 0.5% during the first 48 hours&#xD;
      following dermal application. In these settings, a conventional pharmacokinetic human study&#xD;
      to demonstrate that Mayne Permethrin cream (5% w/w) is bioequivalent to the Reference Listed&#xD;
      Drug [RLD] Elimite™ is not appropriate.&#xD;
&#xD;
      This is a clinical endpoint bioequivalence (BE) study for a Permethrin Cream, 5% formulation&#xD;
      for the treatment of active scabies in comparison to Elimite™ Permethrin cream (5% w/w).&#xD;
&#xD;
        -  Test Product: Permethrin Cream, 5%&#xD;
&#xD;
        -  Reference Product: Elimite™ marketed by Prestium Pharma, Inc. (&quot;Prestium&quot;), the branded&#xD;
           subsidiary of Renaissance Pharma.&#xD;
&#xD;
      The infested person, as well as household members are treated at the same time to prevent&#xD;
      re-infestation. In consideration of this recommendation, the household members of the&#xD;
      enrolled subject will be examined and treated at the same time as the enrolled subject with&#xD;
      an FDA-approved generic Permethrin Cream, 5%.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients That Are Identified as Cured.</measure>
    <time_frame>Day 28</time_frame>
    <description>To demonstrate bioequivalence between Permethrin Cream, 5% (Test) and Elimite™ (Reference) in patients with active scabies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients That Are Identified as Cured.</measure>
    <time_frame>Day 14</time_frame>
    <description>To demonstrate bioequivalence between Permethrin Cream, 5% (Test) and Elimite™ (Reference) in patients with active scabies.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Scabies</condition>
  <arm_group>
    <arm_group_label>Permethrin Cream, 5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Permethrin Cream 5%, topical cream, 60g, maximum of two doses over 28 day treatment duration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elimite</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Elimite™ 60g, topical, marketed by Prestium Pharma, Inc. (&quot;Prestium&quot;), the branded subsidiary of Renaissance Pharma, maximum of two doses over 28 day treatment duration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Permethrin Cream, 5%</intervention_name>
    <description>Subjects on Test product will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.</description>
    <arm_group_label>Permethrin Cream, 5%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elimite</intervention_name>
    <description>Subjects on RLD will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.</description>
    <arm_group_label>Elimite</arm_group_label>
    <other_name>Permethrin Cream, 5%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or non-pregnant, non-lactating female subject at least 12 years of age or older.&#xD;
&#xD;
          2. Subject must have a positive identification for mites, eggs, or mite fecal matter by&#xD;
             microscopic examination of a skin scraping.&#xD;
&#xD;
          3. Subjects must have at least two of the three following: a) excoriations and&#xD;
             inflammatory papules with a typical distribution pattern and localization (webbed&#xD;
             spaces of the fingers, flexor surfaces of the wrists, elbows, axillae, belt line,&#xD;
             feet, skin surface of external genitalia, or areolae); b) presence of burrows; c)&#xD;
             family or contacts with moderate to severe itching which increases during the night.&#xD;
&#xD;
          4. Subjects must be willing to make every effort to immediately disinfect clothes,&#xD;
             towels, and linens and all potentially infected household items upon diagnosis of&#xD;
             infestation to prevent re-infestation.&#xD;
&#xD;
          5. All household members with prolonged physical contact with the subject must be willing&#xD;
             to attend Baseline visit and receive treatment with standard of care if deemed&#xD;
             necessary by the Investigator in order to prevent re-infestation of the subject&#xD;
             enrolled.&#xD;
&#xD;
          6. Subject or representative must read and sign an Institutional Review Board/Independent&#xD;
             Ethics Committee (IRB/IEC) approved Informed Consent Form (ICF); for minor subjects&#xD;
             (18 years or younger in most states) the parent or legal guardian should sign the ICF&#xD;
             and the child will be required to sign the Assent Form that will written in such a way&#xD;
             as to be understandable to a child.&#xD;
&#xD;
          7. Subject must be able to apply study product to self. If the subject is a child, then&#xD;
             parent/guardian will apply study product to him/her.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Females who are pregnant as shown in a urine pregnancy test at the Baseline visit,&#xD;
             prior to randomization, or lactating, or of childbearing potential (for purpose of&#xD;
             this study a female of childbearing potential is considered to be not surgically&#xD;
             sterile or postmenopausal for at least 1 year) who are not using or do not agree to&#xD;
             use an acceptable form of contraception (oral /implant /injectable /transdermal&#xD;
             contraceptives, intrauterine device (IUD), condom, diaphragm, or abstinence) during&#xD;
             the study, or who intends to become pregnant during the study; contraceptive method&#xD;
             must also be consistent throughout the study.&#xD;
&#xD;
          2. Treatment for scabies &lt;4 weeks prior to enrollment, including permethrin, benzyl&#xD;
             alcohol, lindane, crotamiton, malathion, and ivermectin.&#xD;
&#xD;
          3. Use of prohibited medications:&#xD;
&#xD;
               -  Topical or oral scabicidal/antiparasitic treatment including: permethrin, benzyl&#xD;
                  alcohol, benzyl benzoate, lindane, crotamiton, malathion, ivermectin,&#xD;
                  precipitated sulfur, albendazole, keratolytic cream, tea tree oil, or oil of the&#xD;
                  leaves of Lippia multiflora Moldenke within 28 days of visit 2.&#xD;
&#xD;
               -  Systemic corticosteroids (including inhaled steroids) taken within 14 days of&#xD;
                  visit 2.&#xD;
&#xD;
               -  Topical corticosteroids including hydrocortisone taken within 24 hours of visit&#xD;
                  2.&#xD;
&#xD;
               -  Topical antipruritics, including antihistamines within 24 hours of any study&#xD;
                  visits.&#xD;
&#xD;
               -  Oral antihistamine including diphenhydramine (Benadryl) taken within 24 hours of&#xD;
                  any study visits.&#xD;
&#xD;
               -  Topical antibiotics including mupirocin taken within 24 hours of any study&#xD;
                  visits.&#xD;
&#xD;
          4. Patients with immunosuppressive disorders requiring therapy, severe systemic disease,&#xD;
             history of HIV infection and/or seizures.&#xD;
&#xD;
          5. Patients with crusted/Norwegian scabies.&#xD;
&#xD;
          6. Presence of underlying skin disease that would obscure evaluation of the papules and&#xD;
             burrows associated with scabies infection as determined by the Investigator.&#xD;
&#xD;
          7. Presence of severe cutaneous bacterial or fungal infections requiring therapy&#xD;
             (including systemic and topical antibiotics) as determined by the Investigator.&#xD;
&#xD;
          8. Sensitivity or allergy to Permethrin Cream or any of its components, synthetic&#xD;
             pyrethroids, pyrethrin, chrysanthemums or ragweed.&#xD;
&#xD;
          9. A recent (less than 1 year) history of alcoholism, drug abuse, or other problems which&#xD;
             would likely make the subject unreliable for the study.&#xD;
&#xD;
         10. Participation in another investigational study or using any investigational product&#xD;
             within the 30 days prior to the Baseline visit.&#xD;
&#xD;
         11. Participation of family member, or another member of the household (including regular&#xD;
             bedmates) in the current study.&#xD;
&#xD;
         12. Total number of bedmates and family members with prolonged physical contact is greater&#xD;
             than 6 (including study subject).&#xD;
&#xD;
         13. Any employees of the clinic, investigators, or family members of the study staff.&#xD;
&#xD;
         14. Patients who in the opinion of the Investigator would be non-compliant with the&#xD;
             requirements of the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phoevos Hughes, JD</last_name>
    <role>Study Director</role>
    <affiliation>bioRASI, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LCC Medical Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southcoast Research Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Columbia Research</name>
      <address>
        <city>Richland</city>
        <state>Washington</state>
        <zip>99352</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>November 17, 2016</study_first_submitted>
  <study_first_submitted_qc>November 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2016</study_first_posted>
  <results_first_submitted>August 13, 2020</results_first_submitted>
  <results_first_submitted_qc>August 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 2, 2020</results_first_posted>
  <last_update_submitted>August 28, 2020</last_update_submitted>
  <last_update_submitted_qc>August 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scabies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Permethrin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 14, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT02978508/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 14, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT02978508/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Permethrin Cream, 5%</title>
          <description>Permethrin Cream 5%, topical cream, 60g, maximum of two doses over 28 day treatment duration.&#xD;
Permethrin Cream, 5%: Subjects on Test product will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.</description>
        </group>
        <group group_id="P2">
          <title>Elimite</title>
          <description>Elimite™ 60g, topical, marketed by Prestium Pharma, Inc. (&quot;Prestium&quot;), the branded subsidiary of Renaissance Pharma, maximum of two doses over 28 day treatment duration.&#xD;
Elimite: Subjects on RLD will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Permethrin Cream, 5%</title>
          <description>Permethrin Cream 5%, topical cream, 60g, maximum of two doses over 28 day treatment duration.&#xD;
Permethrin Cream, 5%: Subjects on Test product will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.</description>
        </group>
        <group group_id="B2">
          <title>Elimite</title>
          <description>Elimite™ 60g, topical, marketed by Prestium Pharma, Inc. (&quot;Prestium&quot;), the branded subsidiary of Renaissance Pharma, maximum of two doses over 28 day treatment duration.&#xD;
Elimite: Subjects on RLD will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
            <count group_id="B2" value="70"/>
            <count group_id="B3" value="140"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" spread="15.70"/>
                    <measurement group_id="B2" value="36.7" spread="16.23"/>
                    <measurement group_id="B3" value="36.3" spread="15.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Visual Examination of Lesions</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients That Are Identified as Cured.</title>
        <description>To demonstrate bioequivalence between Permethrin Cream, 5% (Test) and Elimite™ (Reference) in patients with active scabies.</description>
        <time_frame>Day 28</time_frame>
        <population>2 subjects were not included in the per protocol anaylis for the following reasons: 101-036: Subject rinsed off the IP after 6:45 mins of application. As per protocol IP is to be rinsed off after at least 8-14 hours of application.&#xD;
103003: Subject's visit 3 and 5 was performed out of allowed visit window period.</population>
        <group_list>
          <group group_id="O1">
            <title>Permethrin Cream, 5%</title>
            <description>Permethrin Cream 5%, topical cream, 60g, maximum of two doses over 28 day treatment duration.&#xD;
Permethrin Cream, 5%: Subjects on Test product will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.</description>
          </group>
          <group group_id="O2">
            <title>Elimite</title>
            <description>Elimite™ 60g, topical, marketed by Prestium Pharma, Inc. (&quot;Prestium&quot;), the branded subsidiary of Renaissance Pharma, maximum of two doses over 28 day treatment duration.&#xD;
Elimite: Subjects on RLD will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients That Are Identified as Cured.</title>
          <description>To demonstrate bioequivalence between Permethrin Cream, 5% (Test) and Elimite™ (Reference) in patients with active scabies.</description>
          <population>2 subjects were not included in the per protocol anaylis for the following reasons: 101-036: Subject rinsed off the IP after 6:45 mins of application. As per protocol IP is to be rinsed off after at least 8-14 hours of application.&#xD;
103003: Subject's visit 3 and 5 was performed out of allowed visit window period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients That Are Identified as Cured.</title>
        <description>To demonstrate bioequivalence between Permethrin Cream, 5% (Test) and Elimite™ (Reference) in patients with active scabies.</description>
        <time_frame>Day 14</time_frame>
        <population>2 subjects were not included in the per protocol anaylis for the following reasons: 101-036: Subject rinsed off the IP after 6:45 mins of application. As per protocol IP is to be rinsed off after at least 8-14 hours of application.&#xD;
103003: Subject's visit 3 and 5 was performed out of allowed visit window period.</population>
        <group_list>
          <group group_id="O1">
            <title>Permethrin Cream, 5%</title>
            <description>Permethrin Cream 5%, topical cream, 60g, maximum of two doses over 28 day treatment duration.&#xD;
Permethrin Cream, 5%: Subjects on Test product will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.</description>
          </group>
          <group group_id="O2">
            <title>Elimite</title>
            <description>Elimite™ 60g, topical, marketed by Prestium Pharma, Inc. (&quot;Prestium&quot;), the branded subsidiary of Renaissance Pharma, maximum of two doses over 28 day treatment duration.&#xD;
Elimite: Subjects on RLD will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients That Are Identified as Cured.</title>
          <description>To demonstrate bioequivalence between Permethrin Cream, 5% (Test) and Elimite™ (Reference) in patients with active scabies.</description>
          <population>2 subjects were not included in the per protocol anaylis for the following reasons: 101-036: Subject rinsed off the IP after 6:45 mins of application. As per protocol IP is to be rinsed off after at least 8-14 hours of application.&#xD;
103003: Subject's visit 3 and 5 was performed out of allowed visit window period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 months from first subject first visit.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Permethrin Cream, 5%</title>
          <description>Permethrin Cream 5%, topical cream, 60g, maximum of two doses over 28 day treatment duration.&#xD;
Permethrin Cream, 5%: Subjects on Test product will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.</description>
        </group>
        <group group_id="E2">
          <title>Elimite</title>
          <description>Elimite™ 60g, topical, marketed by Prestium Pharma, Inc. (&quot;Prestium&quot;), the branded subsidiary of Renaissance Pharma, maximum of two doses over 28 day treatment duration.&#xD;
Elimite: Subjects on RLD will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Upper Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament Sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning Sensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate Director, Clinical Operations</name_or_title>
      <organization>Mayne Pharma LLC</organization>
      <phone>919 573 7948</phone>
      <email>phoevos.hughes@maynepharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

